Tool for diagnosis and prognosis of mature B-cell neoplasms

1. A method of detecting the type of mature B-cell neoplasm present in a sample, said method comprising:

(a) providing a microarray, said microarray comprising a substrate with a plurality of distinct genomic regions and a backbone probe set that covers the entire human chromosomal complement arrayed thereon, wherein the backbone probe set covers the entire chromosomal complement at a resolution with an average density of approximately 1 Mbp, wherein each of the distinct genomic regions is individually capable of hybridizing to material present in said sample, wherein the genomic regions arrayed on the substrate are regions, wherein an alteration therein is correlated to one or more types of mature B-cell neoplasm, wherein the plurality of distinct genomic regions is all of the human genomic regions set forth in Table 6 and wherein the distinct genomic regions are between 0.3 to 21.3 Mbp in size and are represented on the microarray at a resolution with an average density of about 35 kbp;

(b) providing the sample with labeled sample genetic material therein and labeled reference genetic material;

(c) hybridizing the labeled sample genetic material and the labeled reference genetic material with the genomic regions and the backbone probe set arrayed on the substrate;

(d) analyzing the hybridization pattern of the labeled sample genetic material to the genomic regions relative to the hybridization pattern of the reference genetic material to the genomic regions to detect the presence of alterations in the genetic material from the sample; and

(e) correlating any detected alterations to the type of mature B-cell neoplasm associated with the alteration.

2. The method of claim 1 , wherein the mature B-cell neoplasm is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), and multiple myeloma.

3. The method of claim 1 , wherein the mature B-cell neoplasm is CLL.

4. The method of claim 3 , wherein step (e) comprises correlating gains or losses at 2p25.3, 2p16.1-p15, 3q26.31, 3q27, 8p23, 8p21.3, 8q24.21, 11q22.3-q23, 12p13.1, 12q13.1-q13.2, 12q15, 13q14, and 17p13 to CLL.

5. The method of claim 1 , further comprising confirming all of the aberrations set forth in Table 8 by a copy number assay.

6. The method of claim 5 , wherein the copy number assay comprises determining the copy number of: GATA4 and TNFRSF10B for loss of 8p; ATM for loss of 11q; DLEU2 and RB1 for loss of 13q; TP53 for loss of 17p; REL for gain of 2p; BCL6 for gain of 3q; MYC for gain of 8q; and MDM2 for gain of 12.

7. The method of claim 1 , wherein the alteration is the gain or loss of the genomic region or part thereof.

8. The method of claim 1 , wherein labeled sample genetic material and the labeled reference genetic material are hybridized with the genomic regions arrayed on the substrate at the same time.

9. The method of claim 8 , wherein the labeled genetic material comprises a first label and the labeled reference nucleic acid comprises a second label, wherein the first and second labels are non-identical and can be detected simultaneously when hybridized to at least one genomic region on the substrate.

10. The method of claim 9 , wherein step (d) comprises acquiring an image of a microarray including a target spot; processing the image to correct for background noise and chip misalignment; analyzing the image to detect target spots; analyzing the image to identify the target patch, editing debris and correcting for ratio bias; detecting number variation in the target spot by an objective statistical analysis, wherein the sample genetic material and the reference genetic material form the target spot by the hybridizing; measuring a fluorescent signal intensity of the target spot from the sample genetic material and the reference genetic material; obtaining an image; and cross-correlating the image to the image of the microarray.

11. The microarray of claim 1 , wherein the backbone probe set excludes regions of known copy number variation.